Martínez-García A, Cejudo-Álvarez J, Bravo-Topete EG, Herrera-Villalobos JE, Garibay-Valencia M, Mirabent-González F

Language: Spanish
References: 17
Page: 75-85
PDF size: 579.06 Kb.

ABSTRACT

Background: pharmaceutical forms (presentations) influence treatment compliance and therefore the effectiveness. Here we present the results in the relief of vaginitis and vaginosis with two different dosage forms.
Objective: To compare the efficacy and safety of a combination of ketoconazole 800 mg + clindamycin in soft vaginal gel capsules 100 mg (vaginal capsules) against ketoconazole 800 mg + 100 mg clindamycin vaginal tablets (TV) in the management of vaginitis by C. albicans and/or vaginosis.
Material and method: In a randomized, multicenter, comparative open label study, patients between 18 and 60 years with a diagnosis of vaginitis by C. albicans and/or vaginosis were included. Patients were evaluated clinically and direct exam of genital discharge and culture were performed. Patients were randomized to one of two treatments vaginal tablets or vaginal capsules, for 3 days.
Results: one hundred an sitxty nine patients were included, 85 in TV Group and 84 in vaginal capsules group. We found significant statistical difference in clinical response for tablet group at day three for burning p = 0. 032 and itching p = 0. 043. Microbiological cure was observed in patients with vaginitis by C. albicans, 92.5% in Group TV vs. 90.47% vaginal capsules group, all patients with G. vaginalis at baseline were negative for the organism at the end of the study, cure in patients with mixed infections were 78.94% for TV group vs. 78.26% vaginal capsules; group no adverse events were reported during treatment.
Conclusions: Treatment of vaginitis/vaginosis with vaginal tablets is clinically better than vaginal soft gelatin capsules both treatments were well tolerated.

REFERENCES

1. Weir E. Bacterial vaginosis: more questions than answers. CMAJ 2004;171(5):448.

2. Koumans EH, Kendrick JS. Preventing adverse sequelae of bacterial vaginosis: a public health program and research agenda. Sex Transm Dis 2001;28(5):292-297.

3. Holzman C, Leventhal JM, Qiu H, Jones NM, Wang J. Factors linked to bacterial vaginosis in nonpregnant women. Am J Public Health 2001;91(10):1664-1670.

4. Hillier SL. The vaginal microbial ecosystem and resistance to HIV. AIDS Res Hum Retroviruses 1998;14(Suppl 1):S17-S21.

5. Calzolari E, Masciangelo R, Milite V, Verteramo R. Bacterial vaginosis and contraceptive methods. Int J Gynaecol Obstet 2000;70(3):341-346.

6. Amsel R, Totten PA, Spiegel CA, Chen KC, et al. Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations. Am J Med 1983;74(1):14-22.

7. Sobel J, Peipert JF, McGregor JA, Livengood C, Martin M, et al. Efficacy of clindamycin vaginal ovule (3-day treatment) vs clindamycin vaginal cream (7-day treatment) in bacterial vaginosis. Infect Dis Obstet Gynecol 2001;9(1):9-15.

8. Paavonen J, Mangioni C, Martin MA, Wajszczuk CP. Vaginal clindamycin and oral metronidazole for bacterial vaginosis: a randomized trial. Obstet Gynecol 2000;96(2):256-260.

9. Ene MD, Williamson PJ, Daneshmend TK, Blatchford NR. Systemic absorption of ketoconazole from vaginal pessaries. Br J Clin Pharmacol 1984;17(2):173-175.

10. Eckert LO. Clinical practice. Acute vulvovaginitis. N Engl J Med 2006;355:1244-1252.

11. Katz. Vaginitis. Comprehensive Gynecology 2009(5).

12. Samra-Latif OM, Mancini DM, Wood E. Vulvovaginitis. eMedicine Specialties, Obstetrics and Gynecology, General Gynecology 2009 [cited 2009 Feb 24]. Disponible en: .

13. Mandell. Vulvovaginal candidiasis. In: Mandell, Bennett, Dolin, editors. Principles and Practice of Infectious Diseases. 6 ed. Londres: Churchill Livingstone, 2005.

14. Gerhard I, Ohlhorst D, Eggert-Kruse W, Runnebaum B. Topical one-time therapy with ketoconazole: a double-blind randomized study in vaginal mycosis. Mycoses 1989;32(5):253- 265.

15. Smith EB, Henry JC. Ketoconazole: an orally effective antifungal agent. Mechanism of action, pharmacology, clinical efficacy and adverse effects. Pharmacotherapy 1984;4(4):199-204.

16. Ene MD, Williamson PJ, Daneshmend TK, Blatchford NR. Systemic absorption of ketoconazole from vaginal pessaries. Br J Clin Pharmacol 1984;17(2):173-175.

17. Godínez V, Garibay M, Mirabent F, Pérez CA. Comparison of efficacy of combination of ketokonazol 400 mg + clindamycin 100 mg with ketokonazol 800 mg + clindamycin 100 mg in the treatment of vaginitis due to Candida and bacterial vaginosis. Ginecol Obstet Mex 2005;73(6):302- 307.